Brisbane’s world renowned MedTech sector has again been recognised on the global stage, with local company Proseek Bio securing bronze at the Innovator’s Pitch Challenge during J.P. Morgan Healthcare Week in San Francisco.
Proseek Bio, a participant in Brisbane Economic Development Agency’s MedTech Global Accelerator, competed against more than 100 international health technology companies and was recognised for its groundbreaking work in non-invasive blood tests aimed at earlier and more accurate detection of ovarian cancer, an area of significant unmet global health need.
This year’s achievement continues Brisbane’s strong run of podium success at one of the world’s most influential healthcare investor forums, highlighting the city’s growing capability to develop, commercialise and scale life-changing medical technologies.
Brisbane’s Innovator’s Pitch Challenge podium finishes include:
- 2023 Gold: Field Orthopaedics; Bronze: Max Kelsen
- 2024 Silver: Convergence Medical; Bronze: Gelomics
- 2025 Gold: Kimaritec
- 2026 Bronze: Proseek Bio
BEDA’s MedTech Global Accelerator cohort attended the RESI JPM 2026 Investor Forum, in partnership with Life Science Nation, a leading US investor and life sciences networking platform.
Lord Mayor Adrian Schrinner said the result was another strong sign of Brisbane’s rising reputation in health and medical innovation.
“Brisbane’s MedTech talent continues to make waves on the world stage,” Cr Schinner said.
“Proseek Bio’s bronze finish shows just how much innovation is coming out of our city and that Brisbane can go toe-to-toe with the best in the world – especially in lifesaving areas like women’s health and cancer detection.
“We’re proud to support our innovators in building the global connections and partnerships they need to turn great ideas into reality.”
Proseek Bio Founder and CEO, Professor Michelle Hill said the recognition marked a significant milestone for the company.
“Winning bronze in this highly competitive challenge is a tremendous achievement for us,” Professor Hill said.
“It validates the potential of our technology to make a real difference in women’s health and accelerates our ability to attract global partners and investment.
“Support through BEDA’s MedTech Global Accelerator and its international network has been critical to our journey.”
Now in its fourth year, the accelerator has helped more than 30 visionary companies secure $246 million in capital and create more than 250 jobs in Brisbane.
BEDA’s FY26 MedTech Global Accelerator cohort included Aptium AI, BiVACOR, Cool Beans Underwear, Fibrosoft, Ketim Technologies, LORAI Health, Proseek Bio, QBiotics Group Limited, STARCO and Talius.
For more information about the MedTech Initiative, visit https://choose.brisbane.qld.au/business/key-industries/health/medtech
Next Phase Newsletter 
Leave a comment